Meenhard Herlyn

The Wistar Institute — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

136h-index75.2kcitations1.7kworks0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(427), Immunotherapy and Immune Responses(165), Cutaneous Melanoma Detection and Management(132), Cancer Cells and Metastasis(129), Cell Adhesion Molecules Research(108)

Publications1.7k total

SpaceBar enables single-cell-resolution clone tracing with imaging-based spatial transcriptomics
Nature Methods·2025· 1 cited
Supplementary Data Figures S1-S5 from Targeting UGCG Overcomes Resistance to Lysosomal Autophagy Inhibition
2025Open Access
Supplementary Data Tables S1-S2 from Targeting UGCG Overcomes Resistance to Lysosomal Autophagy Inhibition
2025Open Access
DR5 CAR-T cells target melanoma and suppress MDSCs with minimal toxicity
Molecular Therapy·2025Open Access
Supplementary Data from Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma
2025Open Access
Supplementary Figure Legends from Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma
2025Open Access
Supplementary Figures from Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma
2025Open Access
Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors
2025Open Access
Clonal dynamics shaped by diverse drug-tolerant persister states in melanoma resistance
2025Open Access
Modelling Acral Melanoma in Admixed Brazilians Uncovers Genomic Drivers and Targetable Pathways
2025Open Access
DR5 CAR-T cells target solid tumors and suppress MDSCs with minimal toxicity
2025Open Access
Targeting IL13Rα2 in melanoma with a bispecific T-cell engager: expression profiling and preclinical evaluation
Journal for ImmunoTherapy of Cancer·2025Open Access
Facts and Hopes: Toward the Next Quantum Leap in Melanoma
Clinical Cancer Research·2025· 1 citedOpen Access
Heterogeneous therapy-resistant cancer cells have distinct and exploitable drug sensitivity profiles
2025Open Access
Abstract LB213: Heterogeneous expression of IL13Ra2 in melanoma patient-derived xenograft models and targeting with bispecific T cell engager for melanoma therapy
Cancer Research·2025
Abstract 6650: Targeting the PI3K pathway with alpelisib in patient-derived xenografts: a multi-cancer type approach
Cancer Research·2025
Data from Spatiotemporal Profiling Defines Persistence and Resistance Dynamics during Targeted Treatment of Melanoma
2025Open Access
Supplementary Table 2 from Spatiotemporal Profiling Defines Persistence and Resistance Dynamics during Targeted Treatment of Melanoma
2025Open Access
Supplementary Table 6 from Spatiotemporal Profiling Defines Persistence and Resistance Dynamics during Targeted Treatment of Melanoma
2025Open Access
Supplementary Table 1 from Spatiotemporal Profiling Defines Persistence and Resistance Dynamics during Targeted Treatment of Melanoma
2025Open Access
page 1 of 84Next →

Frequent Co-authors

Gao Zhang(9), Xiaowei Xu(8), Peter Arner(7), Keith T. Flaherty(6), Keiran S.M. Smalley(6), Patricia Brafford(6), Rajasekharan Somasundaram(5), Hilary Koprowski(5), David E. Elder(5), Clemens Krepler(5), Zhi Wei(5), Giorgos C. Karakousis(4), Lynn M. Schuchter(4), Yuri Ishizu(4), Michael Detmar(4), Dan Goldowitz(4), Thomas J Ha(4), Akira Hasegawa(4), F. Stephen Hodi(4), Dirk Schadendorf(4)